1. Home
  2. GNK vs OMER Comparison

GNK vs OMER Comparison

Compare GNK & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Genco Shipping & Trading Limited New (Marshall Islands)

GNK

Genco Shipping & Trading Limited New (Marshall Islands)

HOLD

Current Price

$18.77

Market Cap

732.0M

ML Signal

HOLD

Logo Omeros Corporation

OMER

Omeros Corporation

HOLD

Current Price

$11.26

Market Cap

628.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GNK
OMER
Founded
2004
1994
Country
United States
United States
Employees
N/A
N/A
Industry
Marine Transportation
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
732.0M
628.9M
IPO Year
2005
2009

Fundamental Metrics

Financial Performance
Metric
GNK
OMER
Price
$18.77
$11.26
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
5
Target Price
$19.00
$27.50
AVG Volume (30 Days)
568.7K
1.7M
Earning Date
11-05-2025
11-13-2025
Dividend Yield
7.56%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$331,332,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$4.34
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$11.20
$2.95
52 Week High
$19.60
$13.60

Technical Indicators

Market Signals
Indicator
GNK
OMER
Relative Strength Index (RSI) 60.52 71.21
Support Level $18.64 $9.31
Resistance Level $19.45 $11.03
Average True Range (ATR) 0.40 0.65
MACD 0.01 0.17
Stochastic Oscillator 67.86 89.93

Price Performance

Historical Comparison
GNK
OMER

About GNK Genco Shipping & Trading Limited New (Marshall Islands)

Genco Shipping & Trading Ltd is an international shipping company specializing in the transportation of iron ore, coal, grain, steel products and other drybulk cargoes. It is involved in the ocean transportation of drybulk cargoes. The company operates in one segment, with two reportable segment: Major and Minor bulk fleet. It generates revenue through time charter agreements, spot market voyage charters, pool agreements and spot market-related time charters. oyage revenues also include the sale of bunkers consumed during short-term time charters pursuant to the terms of the time charter agreement.

About OMER Omeros Corporation

Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.

Share on Social Networks: